management interviews
Jump to
20 Results Found
  • Not looking at M&A as growth opportunity, would like to grow organically: Glenmark Nov 03, 2017 03:37 PM IST

    Not looking at M&A as growth opportunity, would like to grow organically: Glenmark

    Glenmark Pharma posted stable quarter with a slowdown seen in their Indian business. In an interview to CNBC-TV18, Glenn Saldanha, CMD of Glenmark spoke about the results and his outlook for the company.

  • Cash from out-licensing GBR 830 will be used for repayment of debt: Glenmark Aug 01, 2017 10:56 AM IST

    Cash from out-licensing GBR 830 will be used for repayment of debt: Glenmark

    Glenmark Pharma has announced positive data from a phase 2a study of the molecule GBR 830, which was being studied for moderate-to-severe atopic dermatitis. In an interview to CNBC-TV18, Glenn Saldanha, CMD of the company spoke at length about the molecule.

  • Govt needs to be a strong enabler in pharma sector: Experts Feb 07, 2017 10:14 PM IST

    Govt needs to be a strong enabler in pharma sector: Experts

    Shereen Bhan speaks with top bosses from the pharma sector along with KT Rama Rao, Minister of IT, Telangana at Bioasia 2017 to discuss way forward for pharma sector in making India healthier.

  • New launches to drive earnings growth in FY18 & FY19: Glenmark Dec 20, 2016 11:07 AM IST

    New launches to drive earnings growth in FY18 & FY19: Glenmark

    The company has a strong pipeline of products which the company, CMD Glenn Saldanha said adding that new launches will drive earnings for the company in FY18 and FY19. The company has no plans to raise further capital, he said.

  • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal Dec 20, 2016 10:50 AM IST

    Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

    USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

  • See EBITDA margins at 25% over 10 years: Glenmark CMD Dec 19, 2016 06:16 PM IST

    See EBITDA margins at 25% over 10 years: Glenmark CMD

    The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.

  • Expect better performance from core US biz in Q3: Glenmark Oct 28, 2016 10:35 AM IST

    Expect better performance from core US biz in Q3: Glenmark

    Glenn Saldanha says Zetia Generic - a drug to keep a check on cholestrol levels - will be launched on December 12. The launch could see USD 200-250 million in revenues. The company is going to use the money from here to bring down company's debt.

  • New products, regulatory approvals to drive growth for Glenmark Aug 16, 2016 11:42 AM IST

    New products, regulatory approvals to drive growth for Glenmark

    The company is expecting strong growth in the current fiscal both from India and US. Major approvals are expected to drive growth for Glenmark, says Chairman and Managing Director Glenn Saldanha.

  • Awaiting $45 million from Venezuelan govt: Glenmark Pharma May 13, 2016 10:23 AM IST

    Awaiting $45 million from Venezuelan govt: Glenmark Pharma

    With the big product launch of Ezetimibe (a cholesterol-lowering drug), company's topline revenue to be over 25 percent, where 45 percent will be contributed by the US and 20-25 percent by the Indian business, says Glenn Saldanha, Chairman & MD of Glenmark Pharmaceuticals.

  • Aim is to prevent rampant use of antibiotics: P Lilladher Mar 14, 2016 09:18 AM IST

    Aim is to prevent rampant use of antibiotics: P Lilladher

    Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

  • See 18-20% growth, 10-12 product launches in US: Glenmark Jun 01, 2015 11:25 AM IST

    See 18-20% growth, 10-12 product launches in US: Glenmark

    According to CMD Glenn Saldanha, emerging markets will see positive growth for the company in FY16. The company continues to invest in emerging markets.

  • Sun's margins may reduce to 30-32% post merger: Surajit Pal Dec 29, 2014 12:36 PM IST

    Sun's margins may reduce to 30-32% post merger: Surajit Pal

    As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

  • India Q2 biz has outperformed; maintain guidance: Glenmark Oct 31, 2014 10:29 AM IST

    India Q2 biz has outperformed; maintain guidance: Glenmark

    Glenn Saldanha, chief executive officer, Glenmark says that while the US business has been a drag, India business has been an outperformer for the company.

  • GBR 1302 could be an out-licencing opportunity: Glenmark Aug 20, 2014 11:23 AM IST

    GBR 1302 could be an out-licencing opportunity: Glenmark

    GBR 1302 molecule is a genetically engineered molecule and will be used for the study of breast cancer, says Michael Buschle.

  • Glenmark: Environment challenging, see 20% growth in FY14 May 08, 2013 11:14 AM IST

    Glenmark: Environment challenging, see 20% growth in FY14

    Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.

  • Glenmark to get USD 9 mn upfront: CEO; stk at 52-wk high Dec 24, 2012 10:09 AM IST

    Glenmark to get USD 9 mn upfront: CEO; stk at 52-wk high

    Shares of Glenmark Pharmaceuticals rose over 2 percent to a 52-week high of Rs 512.65 on Monday morning following its agreement with Forest Laboratories on a collaboration for development of inhibitors to treat chronic inflammatory conditions, including pain.

  • May not see 35% growth in H1 sustaining in H2: Glenmark Oct 31, 2012 10:14 AM IST

    May not see 35% growth in H1 sustaining in H2: Glenmark

    Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead.

  • Launches in FY13 to boost growth in Indian market: Glenmark May 09, 2012 11:42 AM IST

    Launches in FY13 to boost growth in Indian market: Glenmark

    Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.

  • Glenmark Pharma sees its India business growing at 23-24% May 11, 2011 10:46 AM IST

    Glenmark Pharma sees its India business growing at 23-24%

    Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.

  • Glenmark confident of US growth despite Tarka issue Mar 14, 2011 11:40 AM IST

    Glenmark confident of US growth despite Tarka issue

    In an interview with CNBC-TV18, Glenn Saldanha, managing director and chief executive officer of Glenmark Pharmaceuticals said,"Tarka is not a major contributor any more to the topline for the US business."

Sections